Quantinno Capital Management LP Has $12.53 Million Stock Position in United Therapeutics Corporation $UTHR

Quantinno Capital Management LP increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 19.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 21,135 shares of the biotechnology company’s stock after acquiring an additional 3,479 shares during the quarter. Quantinno Capital Management LP’s holdings in United Therapeutics were worth $12,533,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter valued at $293,418,000. Avoro Capital Advisors LLC raised its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Janus Henderson Group PLC raised its holdings in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the period. Finally, Baillie Gifford & Co. acquired a new position in United Therapeutics in the 4th quarter worth $157,390,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. Finally, Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $648.33.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $516.31 on Tuesday. The stock has a market cap of $21.92 billion, a P/E ratio of 19.06, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $287.64 and a 52-week high of $609.35. The firm has a 50 day moving average price of $542.59 and a two-hundred day moving average price of $533.07.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.63 earnings per share. Analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Insider Activity

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the sale, the director directly owned 450 shares in the company, valued at approximately $247,765.50. This trade represents a 41.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $518.96, for a total value of $4,930,120.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $168,372,939.28. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 492,833 shares of company stock worth $273,056,767. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.